CIK: 0001909617
Total reported value
$55.6M
Reporting period: 2025-09-30 · Number of holdings: 4
QIMING U.S. VENTURES MANAGEMENT, LLC disclosed 4 holdings in its latest 13F filing for the period ending 2025-09-30, with total reported value of $55.6M and a quarterly turnover rate of 96.6%.
Browse other institutions with under $100M AUMBrowse other institutions starting with "Q"
Sector classification currently covers about 0% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add TRML
0.0% $24.2M
Trim JSPR
0.0% -$1.8M
Add KRRO
0.0% $11.2M
Trim 2KZ0
0.0% -$81.2K
Sold out 43157M102
Sold out VTYXUSD
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TRML | Tourmaline Bio INC | Stock-Other | 63.76% | +14.93% | — | |
| 2 | KRRO | Korro Bio INC | Stock-Other | 31.68% | +3.94% | — | |
| 3 | JSPR | Jasper Therapeutics INC | Stock-Other | 3.97% | -13.32% | — | |
| 4 | 2KZ0 | Kezar Life Sciences INC | Stock-Other | 0.58% | -1.17% | — |
Performance for Q3 2026
—
Performance Last 4 Quarters
—
Based on 36% of reported portfolio value with available pricing
Not enough sector-mapped data yet
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2025-09-30 | 4 | $55.6M | 97 | |
| 2025-06-30 | 6 | $23.6M | 0 | |
| 2025-03-31 | 6 | $23.1M | 0 | |
| 2024-12-31 | 6 | $51.1M | 0 | |
| 2024-09-30 | 6 | $51.4M | 0 | |
| 2024-06-30 | 6 | $52.6M | 0 | |
| 2024-03-31 | 6 | $89.7M | 0 | |
| 2023-12-31 | 8 | $109.2M | 0 | |
| 2023-09-30 | 7 | $75.3M | 0 | |
| 2023-06-30 | 7 | $95.2M | 0 | |
| 2023-03-31 | 7 | $82.6M | 0 | |
| 2022-12-31 | 7 | $75.6M | 0 | |
| 2022-09-30 | 7 | $68.8M | 0 | |
| 2022-06-30 | 7 | $72.0M | 0 | 145114M287410C3471871 |
| 2022-03-31 | 6 | $106.4M | 0 | 187410C245114M3471871 |
| 2021-12-31 | 6 | $217.3M | 0 | 145114M2471871387410C |
Qiming U.s. Ventures Management, LLC's most significant position changes for 2025-09-30: Sold out: Hillevax INC; Sold out: Ventyx Biosciences INC (VTYXUSD).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | TRML | Tourmaline Bio INC | +14.9% | — | Unchanged |
| 2 | KRRO | Korro Bio INC | +3.9% | — | Unchanged |
| 3 | 2KZ0 | Kezar Life Sciences INC | -1.2% | — | Unchanged |
| 4 | JSPR | Jasper Therapeutics INC | -13.3% | — | Unchanged |
| 5 | ✓ | Hillevax INC | — | EXIT | Sold out |
| 6 | VTYXUSD | Ventyx Biosciences INC | — | EXIT | Sold out |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2025-09-30 | 2025-11-10 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-01-28 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-07 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-13 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-14 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-09 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-07-24 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-04-25 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-01-24 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-08 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-07-22 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-16 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001131908
Total reported value
$55.7M
24 stks
2020-06-30
Stale — no recent filing
AUM within 0.1% of this institution
CIK 0001757260
Total reported value
$55.6M
22 stks
2024-03-31
Stale — no recent filing
AUM within 0.1% of this institution
CIK 0001906539
Total reported value
$55.6M
101 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001832749
Total reported value
$49.6M
5 stks
2026-03-31
1 of the top 5 holdings overlap, including Korro Bio INC
CIK 0002103725
Total reported value
$119.7M
5 stks
2026-03-31
1 of the top 5 holdings overlap, including Korro Bio INC